

(Unofficial translation)

DECREE OF THE MINISTRY OF HEALTH OF THE REPUBLIC OF BELARUS
No. 116 dated October 29, 2021

On the establishing a list of strategically important medicinal products

Amendments and additions:

Resolution of the Ministry of Health of the Republic of Belarus of January 27, 2023 No. 16 (National Legal Internet Portal of the Republic of Belarus, 02.04.2023, 8/39474);

Decree of the Ministry of Health of the Republic of Belarus of August 29, 2023 No. 123 (National Legal Internet Portal of the Republic of Belarus, 09.16.2023, 8/40409)

Based on paragraph 3¹ of the Regulation on the procedure and terms of state registration of strategically important medicinal products, approved by Resolution of the Council of Ministers of the Republic of Belarus dated October 8, 2021 No. 570, the Ministry of Health of the Republic of Belarus SHALL DECIDE:

1. To establish a list of strategically important medicinal products in accordance with the annex.
2. This resolution becomes effective after its official publication.

Minister

D. L. Pinevich

Appendix
to Resolution
of the Ministry of Health
of the Republic of Belarus
29.10.2021 No. 116

LIST

Of strategically important medicinal products

1. A medicinal product belonging to the following group, subgroup of the Anatomical-Therapeutic Chemical Classification System of medicinal products (hereinafter the ATC):

- 1.1. A02BC Proton pump inhibitors;
- 1.2. A04A Antiemetic and anti-nausea drugs;
- 1.3. A06AB06 Senna glycosides;
- 1.4. A07E Intestinal anti-inflammatory agents;
- 1.5. A10 Antidiabetic agents;
- 1.6. A14 Anabolic agents for systemic use;
- 1.7. A16AA Amino acids and their derivatives;
- 1.8. A16AB Enzyme preparations;
- 1.9. B01 Antithrombotic agents;
- 1.10. B02 Hemostatic agents;
- 1.11. B03X Other antianemic preparations;
- 1.12. B05 Plasma-substituting and perfusion solutions;
- 1.13. B06AC Hereditary angioedema agents;
- 1.14. C01BD Class III antiarrhythmics;
- 1.15. C01C Cardiotonic agents other than cardiac glycosides;

- 1.16. C01EA Prostaglandins;
- 1.17. C01EB Other heart drugs;
- 1.18. C01EB23 Cardiovascular drugs. Other cardiac medications. Tiazotic acid;
- 1.19. C02KX Antihypertensives for pulmonary hypertension;
- 1.20. C03DA Aldosterone antagonists;
- 1.21. C05CX Other drugs that reduce capillary permeability;
- 1.22. C08CA Dihydropyridine derivatives;
- 1.23. S09VV07 Ramipril and amlodipine;
- 1.24. C09DB Angiotensin II antagonists combined with calcium channel blockers;
- 1.25. C09DX Angiotensin II antagonists combined with other drugs;
- 1.26. C10BA09 Rosuvastatin and fenofibrate;
- 1.27. D01 Antifungals for dermatological use;
- 1.28. D03 Wound and ulcer treatment products;
- 1.29. D04 Anti-pruritic agents including antihistamines, local anesthetics, and other agents;
- 1.30. D05 Psoriasis agents;
- 1.31. D06 Antimicrobials for skin disorders;
- 1.32. D07 Corticosteroids for topical use in skin disorders;
- 1.33. D08 Antiseptics and disinfectants;
- 1.34. D10 Topical acne agents;
- 1.35. D11 Other products for dermatological use;
- 1.36. G02AD Prostaglandins;
- 1.37. G02CB Prolactin release inhibitors;
- 1.38. G03 Sex hormones and modulators of the genital system;
- 1.39. G04BX Other urological agents;
- 1.40. G04CA52 Tamsulosin and dutasteride;
- 1.41. Hormonal agents for systemic use other than hormones and insulins;
- 1.42. J Anti-infectives for systemic use;
- 1.43. L Antitumor and immunomodulatory agents;
- 1.44. M01A Non-steroidal anti-inflammatory and antirheumatic drugs;
- 1.45. M01CC Penicillamine and its similars;
- 1.46. M03 Muscle relaxants;
- 1.47. M04 Anti-gout drugs;
- 1.48. M04AA Inhibitors of uric acid synthesis;
- 1.49. M05B Agents affecting bone structure and mineralization;
- 1.50. N01 Anesthetics;
- 1.51. N02A Opioids;
- 1.52. N02B Other analgesic and antipyretic drugs;
- 1.53. N02C Anti-migraine drugs;
- 1.54. N03 Antiepileptic drugs;
- 1.55. N04 Antiparkinson drugs;
- 1.56. N05A Antipsychotics;
- 1.57. N05B Anxiolytic agents;
- 1.58. N05BA Benzodiazepine derivatives;
- 1.59. N05CD Benzodiazepine derivatives;
- 1.60. N05CF Benzodiazepine-like agents;
- 1.61. N05CM Other hypnotics and sedatives;
- 1.62. N06A Antidepressants;
- 1.63. N07A Parasympathomimetic agents;
- 1.64. N07B Drugs used in the treatment of psychological or physiological dependence on various substances;
- 1.65. N07X Other drugs for the treatment of nervous system diseases;
- 1.66. R03 Drugs for obstructive airway diseases;

- 1.67. R05CA10 Combinations of expectorants;
- 1.68. R06AX Other systemic antihistamines;
- 1.69. R07 Other products for respiratory system diseases;
- 1.70. S Preparations for sense organs diseases;
- 1.71. V01 Allergens;
- 1.72. V03AB Antidotes;
- 1.73. V03AC Iron-binding agents;
- 1.74. V03AF Agents to reduce cytostatic therapy toxicity;
- 1.75. V03A Miscellaneous pharmaceutical products;
- 1.76. V04 Diagnostic agents;
- 1.77. V08 Contrast media;
- 1.78. V09 Diagnostic radiopharmaceuticals;
- 1.79. V10 Therapeutic radiopharmaceuticals.
2. Medicinal product irrespective of an ATC code meeting one of the following criteria:
 - 2.1. Originator pharmaceutical product;
 - 2.2. Biosimilar medicinal product;
 - 2.3. Orphan medicinal product;
 - 2.4. Medicinal product for pediatric use only;
 - 2.5. Generic medicinal product different in the composition of active pharmaceutical ingredients and/or dosage form and/or therapeutic indications from medicinal products already registered;
 - 2.6. Medicinal product developed as part of national programs, national research and technical programs and government scientific programs.
3. Medicinal product matching a similar medicinal product under the ATC pharmacological subgroup and international nonproprietary name which has been added to the Republican Formulary of Medicinal Products and/or the List of Essential Medicines established by Decree of the Ministry of Health of the Republic of Belarus dated July 16, 2007 No. 65 "On the Establishment of the List of Essential Medicines".
4. Traditional Chinese medicine drug.